PFIZER INC.

This document is provided pursuant to Regulation (EC) No 1901/2006 and Communication (2009/C 28/01)

PROPRIETARY DRUG NAME®/GENERIC DRUG NAME:

CHANTIX/VARENICLINE TARTRATE

PROTOCOL NO.:

A3051103

EudraCT NUMBER:

2008-002208-24

PROTOCOL TITLE:

A FOUR WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF VARENICLINE TARTRATE (CP-526,555) IN THE TREATMENT OF POST-HERPETIC NEURALGIA

Study Centers

Data not available

Study Initiation and Final Completion Dates

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.

Phase of Development:

Phase 1

Study Objectives:

1.TO EVALUATE THE ANALGESIC EFFICACY OF VARENICLINE VERSUS PLACEBO IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN)

2.TO EVALUATE THE SAFETY AND TOLERABILITY OF VARENICLINE VERSUS PLACEBO IN PATIENTS WITH POSTHERPETIC NEURALGIA.

3.TO CHARACTERIZE THE PHARMACOKINETICS OF VARENICLINE IN PATIENTS WITH POST-HERPETIC NEURALGIA.

METHODS

Data not available

RESULTS

Subject Disposition and Demography:

Data not available

Efficacy Results:

Data not available

Safety Results:

Data not available

CONCLUSION:

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.